Teva drops development of laquinimod
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Read More
Tag: laquinimod
Teva’s MS pill misses the mark in PhIII trial
Teva Pharmaceutical Industries and partner Active Biotech say a late-stage trial of laquinimod has missed its primary endpoint, with the drug failing to halt the progression of multiple sclerosis in patients with relapsing remitting forms of the disease (RRMS).
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
